Pos­i­tive oc­u­lar im­plant da­ta bring Al­ler­gan one step clos­er to NDA; Vivek Ra­maswamy spawns an­oth­er 'Van­t'

→  In 2016, Brent Saun­der’s Al­ler­gan $AGN or­ches­trat­ed a string of deals af­ter its $160 bil­lion merg­er with Pfiz­er fell through thanks to Oba­ma-era tax rules, in­clud­ing For­Sight VI­SION5 and its glau­co­ma tech­nol­o­gy for $95 mil­lion up­front. But Al­ler­gan al­so has its own in­ter­nal­ly de­vel­oped oph­thal­mol­o­gy pro­gram, its oc­u­lar im­plant bi­mato­prost SR is de­signed to help low­er in­traoc­u­lar pres­sure for at least 4 months in pa­tients strug­gle with eye drops. On Mon­day, Al­ler­gan said a sec­ond Phase III study demon­strat­ed pos­i­tive da­ta adding to the re­sults of a late-stage study re­port­ed in June 2018. An NDA is slat­ed to be sub­mit­ted in the sec­ond half of 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER